Skip to main content

MiNK Therapeutics to Present Three Abstracts on Novel Allogeneic iNKT Programs at SITC

Written by Customer Service on . Posted in Public Companies.

NEW YORK, Oct. 01, 2021 (GLOBE NEWSWIRE) — MiNK Therapeutics, a clinical stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases, today announced acceptance of three abstracts for presentation at the Society for Immunotherapy of Cancer’s (SITC) 36th Annual Meeting being held between November 10-14, 2021.

Presentation Details:

Abstract title: Persistence and tissue distribution of AgenT-797 – a native allogeneic iNKT cell-therapy drug product (NCT04582201 and NCT04754100)
Abstract number: 400
Presenting author: Marco Purbhoo

Abstract title: AgenT-797, a native allogeneic “off-the-shelf” iNKT cell therapy product shows anti-tumor activity in preclinical xenograft models
Abstract number: 205
Presenting author: Burcu Yigit

Abstract title: Identification and characterization of an allogeneic iNKT-CAR targeting BCMA
Abstract number: 135
Presenting author: Xavier Michelet

The full abstracts will be released on Tuesday, November 9, 2021. The updated data will be presented at the conference and will become available in the investor section of our website at http://investor.minktherapeutics.com following the presentation on November 12, 2021.

About MiNK Therapeutics
MiNK Therapeutics is a clinical stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. MiNK is advancing a pipeline of both native and next-generation engineered iNKT programs, with a platform designed to facilitate scalable and reproducible manufacturing for off-the-shelf delivery. The company is headquartered in New York, NY. For more information, please visit https://minktherapeutics.com/ and follow MiNK on LinkedIn and Twitter @MiNK_iNKT.

Contact
MiNK Therapeutics
Kimberly Ha
KKH Advisors
917-291-5744
kimberly.ha@kkhadvisors.com

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.